Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54.7M
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
51.1M
-
Shares change
-
+6.68M
-
Total reported value, excl. options
-
$411M
-
Value change
-
+$48.3M
-
Put/Call ratio
-
0.16
-
Number of buys
-
57
-
Number of sells
-
-49
-
Price
-
$8.05
Significant Holders of Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) as of Q3 2023
140 filings reported holding MRNS - Marinus Pharmaceuticals, Inc. - Common Stock as of Q3 2023.
Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.1M shares
of 54.7M outstanding shares and own 93.3% of the company stock.
Largest 10 shareholders include SUVRETTA CAPITAL MANAGEMENT, LLC (5.2M shares), EVENTIDE ASSET MANAGEMENT, LLC (4.53M shares), BlackRock Inc. (4.15M shares), FRANKLIN RESOURCES INC (3.78M shares), Avoro Capital Advisors LLC (3.15M shares), JENNISON ASSOCIATES LLC (2.96M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.9M shares), Cormorant Asset Management, LP (2.63M shares), VANGUARD GROUP INC (2.58M shares), and Lion Point Capital, LP (2.15M shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.